Lumida
/ALT
⌘K
Altimmune Inc

Altimmune Inc

ALT
$3.11USD↓-4.01%-0.13 today

MARKET CAP

604.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In the Stage 4 decline, ALT remains in a lower-high/lower-low sequence below all major EMAs. Price action is sideways and indecisive around the 9/21 EMA band with RSI neutral. Medium-term structure is bearish while the long-term trend stays up. Execution calls for trimming into rallies up to the EMA resistance zone.

  • ↑$519M cash covers expenses through 2027 and 2029 pemvidutide readouts, reducing near-term financing risk.
  • ↑Phase 2 pemvidutide trials for AUD and MASH show significant efficacy trends, opening multi-indication potential.
  • ↓Zero revenues last quarter underscore reliance on equity raises and potential dilution.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Altimmune, Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for infectious diseases, liver diseases, and metabolic disorders. The firm is currently centered around its main asset, pemvidutide, which is being tested for conditions such as alcohol use disorder (AUD) and metabolic dysfunction-associated steatohepatitis (MASH). As Altimmune works on its pipeline, it remains a notable player in the growing biopharmaceutical sector, leveraging its promising therapies to potentially address unmet medical needs.

Bull says

  • ↑$519M cash covers expenses through 2027 and 2029 pemvidutide readouts, reducing near-term financing risk.
  • ↑Phase 2 pemvidutide trials for AUD and MASH show significant efficacy trends, opening multi-indication potential.
  • ↑Analyst consensus (4 Buys, 50% Strong Buys) with $13.50 average PT signals market upside expectation.
  • ↑Recent 2.08% stock gain and pivot-point buy signal indicate resilient momentum amid sector headwinds.
  • ↑High institutional ownership and solid liquidity support smoother share rotations and potential inflows.
  • ↑Modest dividend yield adds income appeal alongside growth-driven pipeline thesis.

Bear says

  • ↓Zero revenues last quarter underscore reliance on equity raises and potential dilution.
  • ↓Heavy R&D spending drives operating losses; EPS forecast remains negative at -$0.58 next fiscal year.
  • ↓High leverage elevates financing risk and potential share dilution amid cash burn.
  • ↓Volatility and 57% short interest reflect market skepticism and downside pressure.
  • ↓Delayed pemvidutide results through 2027–2029 increase timeline risk and investor uncertainty.
  • ↓Negative earnings yield and poor profitability signal valuation risk absent clinical catalysts.

Investment themes with ALT

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-13-2026neutral

Transcript signals

Read full transcript analysis ›